Futuro del CRPC. Visión 360º

14 / 28

AR-V7 Adna test
Antonarakis et al. N Engl J Med 2014
Treatment1
Baseline
AR-V7+
Response
AR-V7
status PSA50 P- value rPFS P- value OS (95% CI) P value
Abiraterone
(N=31) 19% (6/31)
+ 0% (0/6)
.004
2.3 mos
<.001
10.6 mos (8.5–NR)
.002
– 68% (17/25) >6.3 mos >11.9 mos (11.9–NR)
Enzalutamide
(N=31) 39% (12/31)
+ 0% (0/12)
.004
2.1 mos
<.001
5.5 mos (3.9–NR)
.006
– 53% (10/19) 6.1 mos NR (NR–NR)